和铂医药-B(02142.HK):巴托利单抗治疗全身型重症肌无力试验获积极研究结果
和铂医药-B(02142.HK)公布,巴托利单抗(HBM9161)治疗全身型重症肌无力的III期临床试验的积极研究结果。该关键临床研究旨在确认巴托利单抗在治疗中国gMG患者时的疗效及安全性,是继2021年8月完成的用于治疗中国gMG患者的概念验证研究取得积极成果之后的又一里程碑。
公司指,正在大中华区开发巴托利单抗,初步专注于重症肌无力、免疫性血小板减少症、视神经脊髓炎谱系疾病、甲状腺相关性眼病、慢性炎性脱髓鞘性多发性神经根神经病等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.